Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation

The Journal of Clinical Investigation
M WellerA Fontana

Abstract

The majority of human malignant glioma cells express Fas/APO-1 and are susceptible to Fas/APO-1 antibody-mediated apoptosis in vitro. The sensitivity of Fas/APO-1-positive glioma cell lines to Fas/APO-1 antibody-mediated killing correlates inversely with the constitutive expression of the antiapoptotic protooncogene bcl-2. Here we report that BCL-2 protein expression of human glial tumors in vivo correlates with malignant transformation in that BCL-2 immunoreactive glioma cells were more abundant in WHO grade III/IV gliomas than in grade I/II gliomas. Fas/APO-1 antibody-sensitive human glioma cell lines stably transfected with a murine bcl-2 cDNA acquired resistance to Fas/APO-1 antibody-mediated apoptosis. Forced expression of bcl-2 also attenuated TNF alpha-mediated cytotoxicity of glioma cell lines in the presence of actinomycin D and cycloheximide and conferred partial protection from irradiation and the cancer chemotherapy drugs, cisplatin and BCNU. Preexposure of the glioma cell lines to the cytokines, IFN gamma and TNF alpha, which sensitize for Fas/APO-1-dependent killing, partially overcame bcl-2-mediated rescue from apoptosis, suggesting that multimodality immunotherapy involving cytokines and Fas/APO-1 targeting migh...Continue Reading

References

Oct 1, 1992·The Journal of Experimental Medicine·M K CollinsA Lopez-Rivas
Jul 1, 1992·Journal of Neurosurgery·J YoshidaK Kurisu
Aug 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·D M HockenberyS J Korsmeyer
Sep 1, 1987·European Journal of Immunology·K FreiA Fontana
Oct 22, 1993·Cell·D M HockenberyS J Korsmeyer
Oct 1, 1994·The Journal of Experimental Medicine·M G CifoneR Testi
Nov 1, 1994·European Journal of Immunology·B C RichardsonR M Marks
Jan 1, 1993·The Journal of Experimental Medicine·E RouvierP Golstein
Jun 1, 1994·The Journal of Experimental Medicine·S D GriffithsM Greaves
Jan 1, 1994·The Journal of Cell Biology·J C Reed
Jan 15, 1993·International Journal of Radiation Oncology, Biology, Physics·A TaghianH Suit
Mar 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·G Deng, E R Podack

❮ Previous
Next ❯

Citations

Jul 29, 1998·International Journal of Cancer. Journal International Du Cancer·U Naumann, M Weller
Dec 8, 1998·International Journal of Cancer. Journal International Du Cancer·M WellerJ Dichgans
Apr 7, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·U WüllnerT Klockgether
Jan 17, 2002·The Journal of Pathology·Tineke TimmerSteven de Jong
Oct 1, 1996·Molecular and Cellular Biochemistry·H J Brömme, J Holtz
Aug 24, 2001·Brain Tumor Pathology·M IchinoseK Tabuchi
Jan 1, 1996·Immunologic Research·E Schattner, S M Friedman
Jun 16, 2007·Cancer Immunology, Immunotherapy : CII·Diego O CrociO Graciela Scharovsky
Jun 11, 2010·Journal of Neuro-oncology·Katarzyna KoslaAndrzej K Bednarek
Apr 9, 2002·Current Neurology and Neuroscience Reports·Joachim P Steinbach, Michael Weller
Apr 24, 2010·Molecular Neurobiology·Bartlomiej B OrdysIan R Whittle
Feb 1, 1996·Molecular Aspects of Medicine·D J McConkeyS Orrenius
Oct 26, 2000·European Journal of Pharmacology·M VietorM Weller
Apr 30, 1998·Journal of the Neurological Sciences·L RiegerR Meyermann
Feb 2, 2000·Urology·N NonomuraA Okuyama
May 5, 2001·Brain Research. Brain Research Reviews·M Bredel
Jun 1, 1996·Mutation Research·M L Smith, A J Fornace
Jul 22, 1998·Journal of Neuroimmunology·W RothM Weller
Mar 1, 2000·Journal of Neuroimmunology·A R DixL A Morford
Mar 19, 1999·Immunology Today·J O'ConnellF Shanahan
Jul 31, 1998·Cancer Letters·M WellerM Schabet
Feb 23, 2000·Neuroscience·A M GormanS Ceccatelli
Dec 4, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D Del BufaloG Zupi
Apr 20, 2004·Critical Reviews in Oncology/hematology·Jan Maxwell NørgaardPeter Hokland
Oct 30, 1998·Critical Reviews in Oncology/hematology·M ClynesK Scanlon
Nov 17, 1999·Neuropathology and Applied Neurobiology·M B DelgadoS B Wharton
Sep 1, 1996·The Journal of Experimental Medicine·J O'ConnellF Shanahan
Sep 4, 2003·Human Gene Therapy·Ulrike NaumannMichael Weller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.